Optellum, a prominent figure in AI-driven clinical support for early lung cancer diagnosis, has revealed its groundbreaking multimodal therapy AI guidance platform for life science research.

This innovative AI software, accompanied by its promising scientific findings, will make its debut at the 2024 ASCO Annual Meeting in Chicago from May 31st to June 4th.

Lung cancer often remains asymptomatic until reaching an advanced stage, limiting treatment options and leading to poorer outcomes.

However, by analyzing the 90 million CT scans performed annually on US patients, there's potential to establish an "early detection system." Optellum's Virtual Nodule Clinic.

The first FDA-cleared decision support system for early-stage lung cancer, combines Patient Discovery AI with a clinically validated Lung Cancer Prediction (LCP) score derived from imaging AI/Radiomics.

This integration assists clinicians in identifying high-risk patients across healthcare systems and prioritizing them for follow-up interventions.

Early diagnosis offers patients access to curative treatment options. Yet, 30% to 60% of Stage I-II NSCLC patients may still experience recurrence post-surgery.

Accurately assessing recurrence risk could enable thoracic oncology teams to optimize treatment strategies early on, such as tailoring surgical resection and providing timely neo-adjuvant and peri-operative treatments.

For drug developers, this approach could aid in risk-stratifying populations, increasing treatment rates, broadening indications to earlier stages, and predicting treatment response.

Optellum will present their precision lung cancer care AI solutions. During the Poster Session on June 3rd at 1:30 pm, Optellum's clinical partners will unveil results of AI-guided recurrence prognosis in Stage I-III NSCLC from multi-modal pre-surgical data. 

Demonstrating significantly improved sensitivity for recurrence compared to traditional staging methods. Additionally, Optellum's AI solutions will be showcased at the CancerLinQ booth (#14013) and the ConcertAI booth (#12045).

Optellum, can be an effective non-invasive technology to optimize decision making early in the patient's journey, which may help to improve outcomes."

Multi-modal AI platform aims to serve as the 'operating system' guiding precision lung cancer care throughout the patient journey, from early identification to predicting response and monitoring.

Neo-adjuvant therapies are transformative, and in collaboration with our medtech and biopharma partners, we leverage AI's power to democratize access to life-saving early diagnosis and precision treatment for all eligible patients."

 

 

 

 

Source: prnewswire.com

Report Abuse